Rigel Pharmaceuticals RIGL Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Rigel Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rigel Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rigel Pharmaceuticals's stock issuance proceeds?
- Rigel Pharmaceuticals (RIGL) reported stock issuance proceeds of $321K in Q1 2026.
- How has Rigel Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Rigel Pharmaceuticals's stock issuance proceeds decreased by 33.7% year-over-year, from $484K to $321K.
- What is the long-term trend for Rigel Pharmaceuticals's stock issuance proceeds?
- Over 4 years (2021 to 2025), Rigel Pharmaceuticals's stock issuance proceeds has grown at a 14.1% compound annual growth rate (CAGR), from $4.78M to $8.1M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.